Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12g Title Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] ASSETS Current assets: Cash Accounts receivable, net Grant receivable Inventory Prepaid expenses Total current assets [Assets, Current] Property and equipment, net Right to use assets Other assets: Intangible assets, net Goodwill Deposits, long term Total other assets [Other Assets] Total assets [Assets] LIABILITIES AND DEFICIT Current liabilities: Accounts payable and accrued expenses, including related party payables of $1,448,722 and $1,271,685, respectively Deferred revenue, grant Lease liability, short term Notes payable, net of debt discount of $0 Notes payable, related parties, net of debt discount of $0 Total current liabilities [Liabilities, Current] Long term liabilities: Economic Injury Disaster loan, long term Upfront purchase price liability Royalty liability Royalty obligation, net of discount of $3,707,374 and $3,941,262, related parties Lease liability, long term Total liabilities [Liabilities] Commitments and contingencies Deficit: Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025 Common stock, $0.001 par value; 750,000,000 shares authorized, 29,666,506 and 24,489,311 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common stock subscribed Additional paid in capital Accumulated deficit Total deficit attributable to BioCorRx Inc. [Equity, Attributable to Parent] Non-controlling interest Total deficit [Equity, Including Portion Attributable to Noncontrolling Interest] Total liabilities and deficit [Liabilities and Equity] Convertible Series A Preferred Stock [Member] Convertible Series B Preferred Stock [Member] Related party payables Debt discount on notes payable Related party debt discount on notes payable Discount on Royalty obligation related parties Preferred Stock, Shares Authorized Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Preferred Stock, Shares Designated Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Revenues, net Operating expenses: Cost of goods sold Research and development Selling, general and administrative Impairment of intellectual property Depreciation and amortization Total operating expenses [Operating Expenses] Loss from operations [Operating Income (Loss)] Other income (expenses): Interest expense - related parties [Interest expense - related parties] Interest expense, net [Interest Expense, Operating and Nonoperating] Loss on settlement of debt Grant income Change in fair value of upfront purchase price liability Change in fair value of royalty liability Other miscellaneous income Total other income [Nonoperating Income (Expense)] Loss before provision for income taxes [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Income taxes Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Non-controlling interest [Net Income (Loss) Attributable to Noncontrolling Interest] Net loss attributable to BioCorRx Inc. [Net Income (Loss) Attributable to Parent] Net loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted CONDENSED CONSOLIDATED STATEMENT OF DEFICIT (UNAUDITED) Equity Components [Axis] Series A Convertible Preferred Stocks Series B Convertible Preferred Stock Common Stock Common Stock Subscribed Additional Paid-In Capital Accumulated Deficit Noncontrolling Interest Balance, shares [Shares, Issued] Balance, amount Common stock issued for services rendered, shares Common stock issued for services rendered, amount Common stock issued in connection with issuance of promissory notes, shares Common stock issued in connection with issuance of promissory notes, amount Common stock issued in connection with conversion of promissory notes and accounts payable, shares Common stock issued in connection with conversion of promissory notes and accounts payable, amount Common stock issued in connection with exercise of warrants, shares Common stock issued in connection with exercise of warrants, amount Common stock issued in connection with APA (Note 4), shares Common stock issued in connection with APA (Note 4), amount Warrants issued in connection with APA (Note 4) Share-based compensation Imputed interest for related party advances Net loss Common stock issued in connection with subscription agreement, shares Common stock issued in connection with subscription agreement, amount Common stock issued in connection with conversion of promissory notes, shares Common stock issued in connection with conversion of promissory notes, amount Common stock issued in connection with acquisition of non-controlling interest, shares Common stock issued in connection with acquisition of non-controlling interest, amount Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to cash flows used in operating activities: Depreciation and amortization Amortization of discount on royalty obligation Amortization of debt discount Impairment of intellectual property Amortization of right-of-use asset Loss on settlement of debt Inventory write-down Change in fair value of upfront purchase price liability [Change in fair value of upfront purchase price liability] Change in fair value of royalty liability Stock based compensation Imputed interest for related party advances Changes in operating assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Grant receivable [Increase (Decrease) in Other Receivables] Inventory [Increase (Decrease) in Inventories] Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued expenses Royalty liability [Increase (Decrease) in Royalties Payable] Upfront purchase price liability [Upfront purchase price liability] Lease liability Deferred revenue, grant [Increase (Decrease) in Deferred Revenue] Net cash used in operating activities [Cash Provided by (Used in) Operating Activity, Including Discontinued Operation] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from common stock subscription and royalty agreement Payment to Economic Injury Disaster loan [Payment to Economic Injury Disaster loan] Payment of notes payable - related party [Repayments of Related Party Debt] Payment of notes payable [Repayments of Notes Payable] Proceeds from notes payable - related party Net cash provided by financing activities [Cash Provided by (Used in) Financing Activity, Including Discontinued Operation] Net (decrease) increase in cash [Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation] Cash, beginning of period Cash, end of period Supplemental disclosures of cash flow information: Interest paid Taxes paid Noncash Investing and Financing Items Common stock issued in connection with conversion of promissory notes and accounts payable Common stock issued in connection with conversion of related party promissory note Common stock issued in connection with APA (Note 4) Warrants issued in connection with APA (Note 4) [Warrants issued in connection with APA (Note 4)] Conversion of accrued interests to principal of promissory notes Common stock issued in connection with issuance of promissory notes Insider Trading Arrangements Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non Rule 10b5-1 Arrangement Adopted [Flag] Non Rule 10b5-1 Arrangement Terminated [Flag] BUSINESS BUSINESS Business Description and Basis of Presentation [Text Block] SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] GOING CONCERN AND MANAGEMENTS LIQUIDITY PLANS GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS BUSINESS COMBINATION BUSINESS COMBINATION Business Combination [Text Block] PREPAID EXPENSES PREPAID EXPENSES Other Current Assets [Text Block] PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] LEASE LEASE Lessee, Operating Leases [Text Block] INTANGIBLE ASSETS INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] ACCOUNTS PAYABLE AND ACCRUED EXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] NOTES PAYABLE NOTES PAYABLE Debt Disclosure [Text Block] NOTES PAYABLERELATED PARTIES NOTES PAYABLE-RELATED PARTIES ECONOMIC INJURY DISASTER LOAN ECONOMIC INJURY DISASTER LOAN [ECONOMIC INJURY DISASTER LOAN] ROYALTY OBLIGATIONS NET ROYALTY OBLIGATIONS, NET STOCKHOLDERS EQUITY (DEFICIT) STOCKHOLDERS' EQITY /(DEFICIT) STOCK OPTIONS AND WARRANTS [STOCK OPTIONS AND WARRANTS] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] CONCENTRATIONS CONCENTRATIONS Concentration Risk Disclosure [Text Block] NON-CONTROLLING INTEREST [NON-CONTROLLING INTEREST] COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] SEGMENT INFORMATION SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] CONTINGENT PAYMENT CONTINGENT PAYMENT [CONTINGENT PAYMENT] REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS [REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] Interim Financial Statements Revision of Previously Issued Interim Financial Statements Basis of Presentation Revenue Recognition Deferred Revenue-Grant Use of Estimates Accounts Receivable Inventory Inventory, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value Measurements Business Combinations and Contingent Consideration Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Segment Information Long-Lived Assets Intangible Assets Property and Equipment Leases Net (loss) Per Share Advertising Grant Income Research and development costs Stock Based Compensation Income Taxes Variable Interest Entity Non-Controlling Interest Royalty Obligations, net Recent Accounting Pronouncements Schedule of net sales Schedule of Inventory Schedule of antidilutive securities Schedule of assets acquired and liabilities Schedule of assumptions used for fair value of warrant Schedule of fair value of the identifiable intangible assets Schedule of prepaid expenses Schedule of property and equipment Schedule of lease liability Schedule of maturity of lease agreements Schedule of lease cost Schedule of Weighted-average remaining lease term Schedule of intangible assets Schedule of future amortization of patents Schedule of accounts payable and accrued expenses Schedule of outstanding notes payable Schedule of outstanding notes payable related party Schedule of future principle payments Schedule of stock options activity Schedule of information regarding stock options Schedule of changes in warrants outstanding and the related prices Summary of warrant activity Schedule of net loss attributable to non-controlling interest Schedule of changes in non-controlling interest Schedule of segment information Schedule of contingent payments REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Tables) Schedule of condensed consolidated balance sheet Schedule of condensed consolidated statment of operations Schedule of condensed consolidated statment of deficit Schedule of condensed consolidated statment of cash flows Ownership [Axis] BioCorRx Pharmaceuticals, Inc [Member] Management fee Ownership retained percent Acquired an additional ownership interest Common stock issued for services rendered, shares Sales/access fees Supply and distribution sales Net sales Raw materials Finished goods Inventory Shares underlying options outstanding Shares underlying warrants outstanding Convertible preferred stock outstanding Total [Weighted Average Number of Shares Outstanding, Diluted, Adjustment] Exercise Price Range [Axis] Minimum [Member] Maximum [Member] Allowance for doubtful accounts Advertising costs [Marketing and Advertising Expense] Goodwill impairment Intangible assets impairment Deferred Revenue Advertising costs Grant funding during the first year Grant funding Grant funding during the second year Grant funding during the third year Grant additional funding during the third year Grant receivables Deferred revenues related to grant Grant income [Grant income] Research and development expenses Ownership percentage Royalty obligations description Description of Non-Controlling Interest Royalty obligations, net Property plant and equipment estimated useful lives Award Type Axis Plan Name Axis Related Party Transaction [Axis] Related Party [Axis] February 22, 2024 [Member] Unsecured Promissory Note Related Third Party [Member] 2026 Q1 Lucido Subscription Agreement [Member] Joseph Galligan [Member] Mr Lucido [Member] Common stock shares issued [Stock Issued During Period, Shares, New Issues] Common stock shares value Working capital deficit Cash [Cash] Net cash used in operating activities Gross Proceeds from issuance of promissory notes Promissory note outstanding Common stock shares issued Common stock price per share Description of funding Award granted by third party Amendment description Upfront purchase price Royalty payments Stock consideration Warrant consideration Total [Business Combination, Contingent Consideration, Liability] Inventories Trademarks (included in intangibles) Customer base (included in intangibles) Other payable [Business Combination, Recognized Liability Assumed, Other Liability, Current] Total identifiable net assets Goodwill Risk-free interest rate Expected term (years) Expected volatility Expected dividends Indefinite-Lived Intangible Assets [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Trademarks [Member] Customer [Member] Estimated useful life Estimated useful life [Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life] Trademarks (included in intangibles) Customer base (included in intangibles) Sellers retention description Common stock shares issued Closing market price Common stock price per share Common stock purchased Exercise price Fair value of stock issued Royalty payments Upfront purchase price [Upfront purchase price] Discounted at the risk-free rate Discounted at required metric risk premium Prepaid insurance Prepaid subscription services Other prepaid expenses Total Office equipment Computer equipment Manufacturing equipment Leasehold improvement Property and equipment, gross Less accumulated depreciation [Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment] Property and equipment, net Depreciation expense Total lease liability Less: short term portion Long term portion 2026 2027 2028 2029 Subtotal Less: Present value discount Lease liability Operating lease expense Total lease expense Weighted-average remaining lease term Lease Contractual Term [Axis] Lease Agreement [Member] Maximum [Member] Minimum [Member] Right to use assets and lease liability Total lease expense [Operating Lease, Lease Income] Monthly lease payments Right to use assets and lease liability [Right-of-Use Asset Obtained in Exchange for Operating Lease Liability] Expiry date Lease rental payment, monthly Patents [Member] Customer Base [Member] Intangible assets, gross Less accumulated amortization [Finite-Lived Intangible Assets, Accumulated Amortization] Intangible assets, net [Finite-Lived Intangible Assets, Net] 2026 [Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year] 2027 [Finite-Lived Intangible Asset, Expected Amortization, Year One] 2028 [Finite-Lived Intangible Asset, Expected Amortization, Year Two] 2029 [Finite-Lived Intangible Asset, Expected Amortization, Year Three] 2030 and after Total future amortization of the patents Title Of Individual Axis Naltrexone Implant Formulation [Member] Australia from Trinity Compound Solutions [Member] Intellectual Property [Member] Amortization expense Intangible assets acquired fair value Accumulated amortization Patent acquired purchase price Estimated useful lives Impairment of intellectual property [Impairment of Ongoing Project] Accounts payable Interest payable on notes payable Interest payable on notes payable, related parties Deferred insurance Accrual of interest and loss on contingency Interest payable on EIDL loan Line of Credit Accrual of interest on unpaid upfront purchase price Accrued expenses Account payable accrued expenses Short-Term Debt, Type [Axis] Promissory note payable one Promissory note payable two Promissory note payable three Promissory note payable four Promissory note payable five Promissory note payable six Advances from third party Total Outstanding notes payable Debt instrument due date Debt discount, net Award Date Axis September 9, 2021 [Member] Third Party [Member] October 6, 2022 [Member] January 25, 2023 [Member] November 10, 2023 [Member] December 8, 2023 [Member] March 14 2024 [Member] Interest rate during period Repayment of debt principal payments [Repayment of debt principal payments] Repayment of debt principal payments Interest rate increased Due to related party Interest payable on note payable Unsecured promissory note payable Outstanding balance of note Promissory note issued Promissory note issued [Promissory note issued] Proceeds from issuance of debt Promissory notes payable Promissory Notes payable Debt instrument lum sum payment Debt instrument lum sum payment [Debt instrument lum sum payment] Restricted stock price per share Restricted stock price per share [Restricted stock price per share] Restricted stock value Restricted stock shares issued Exercise price [Stock Option, Exercise Price, Decrease] Interest rate Convertible conversion price increase Convertible conversion price Conversion price Convertible conversion price decrease Interest expense Interest expense debt Debt extinguishment loss Warrant exercise price Warrant issued Interest payment Notes payable, net of debt discounts Derivative liability and debt discount Common stock issued Common stock issued, value Common stock value Debt discount interest expense Kent Emry [Member] Louis C Lucido [Member] Lourdes Felix [Member] Advances from related parties Notes payable to related parties 2026 [Member] Louis Lucido [Member] Interest expense - related parties [Interest expense - related parties 1] Outstanding balance of advances Promissory note outstanding Due to related party Interest expense amortization Unsecured promissory notes issued Interest expense Interest rate [Debt Conversion, Converted Instrument, Rate] Proceds from advance Accumulated interest notes payable Due from related party Principal payments (monthly) Outstanding balance note 2026 [Finance Lease, Liability, to be Paid, Next Rolling 12 Months] 2027 [Finance Lease, Liability, to be Paid, Rolling Year Two] 2028 [Finance Lease, Liability, to be Paid, Rolling Year Three] 2029 [Finance Lease, Liability, to be Paid, Rolling Year Four] 2030 and after [Finance Lease, Liability, to be Paid, after Rolling Year Five] Total [Finance Lease, Liability, to be Paid] July 17, 2020 [Member] Economic Injury Disaster Loan assistance program [Member] April 28, 2020 [Member] Accumulated interest on EIDL Loan Balance of principal and interest payable description Proceeds from EIDL loan Interest rate Payments of interest Monthly payments of principal and interest Advances from SBA Joseph Galligan [Member] Amortized Interest expense Non-cash interest expense Expected life of the arrangement Royalty agreements description Ownership percentage Extinguishment of Debt [Axis] Class Of Warrant Or Right Axis Related Party [Member] Common Stocks [Member] Board of Directors [Member] Convertible promissory notes [Member] Convertible accounts payable [Member] Warrants [Member] Preferred stock, shares authorized Preferred stock series A, shares issued Preferred stock series A, shares outstanding Description of convertible preferred stock Convertible preferred stock description Common share issued for services Common share issued for compensation, shares Common share issued for compensation, value Common share issued for services, shares Common share issued for promissory notes, value Common share issued for promissory notes, shares Ownership interest Shares issued as consideration value Debt converted into equity Accounts payable Common stock issued for services rendered Common Stock, Shares Issued Per share price of stock issued during the period Total purchase price Common Stock, Shares Outstanding Price per shares Number of Shares Outstanding, Beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number] Shares, Expired [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period] Outstanding, Ending Exercisable at Ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number] Weighted Average Exercise Price Outstanding, Beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Weighted Average Exercise Price, Expired Outstanding, Ending Exercisable at Ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price] Weighted Average Remaining Contractual Term Outstanding, Beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term] Outstanding at Ending Exercisable at Ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term] Aggregate Intrinsic Value Outstanding, Beginning [Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding] Outstanding at Ending Exercisable at Ending [Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value] Financial Instrument Axis Options Exercisable [Member] 0.01-2.50 [Member] 2.51-5.00 [Member] 5.01 And Up [Member] Options Outstanding [Member] Exercisable, Number of Options Weighted average remaining life in years Number of options Warrants Outstanding [Member] Warrants Exercisable [Member] 0.55 [Member] Weighted average remaining life in years Exercisable, Number of Options Exercise price [Warrant, Exercise Price, Increase] Number of outstanding Weighted Average Exercise Price, Expired 2014 Equity Incentive Plan [Member] 2016 Equity Incentive Plan [Member] 2018 Equity Incentive Plan [Member] 2022 Equity Incentive Plan [Member] 2025 Q4 SPA [Member] 2025 Q4 Subscription Agreement [Member] Q4 Exchange Agreement [Member] Alpha [Member] Third Parties [Member] Stock price Exercise price Stock compensation expense Proceeds from issuance of common stock Description of warrants shares Description of third amendment agreement Purchase of common stock, shares Common stock shares issued Warrants to purchase shares of common stock Exercise price [Stock Option, Exercise Price, Increase] Granted Aggregate total of granted shares under the plan Issued and outstanding shares percentage Issued warrant to purchase common stock Price per share Outstanding debt balance Shares of common stock issued in exchange Purchase price BioCorRx Inc. [Member] Director [Member] BioCorRx Pharmaceuticals [Member] Common stock shares issued in exchange Compensation and interest payable Ownership retained percent [Ownership retained percent] Ownership interest [Subsidiary, Ownership Percentage, Parent] Concentration Risk By Benchmark Axis Accounts Receivable [Member] Two Customers [Member] Sales Revenue [Member] Accounts receivable, net [Accounts Receivable, after Allowance for Credit Loss] Concentration risk Concentration risk, percentage Consolidated Entities Axis Joseph DeSanto MD [Member] Average Non-controlling interest percentage of profit/losses Net loss attributable to the non-controlling interest Total [Total] Beginning Balance Net loss attributable to the non-controlling interest Acquisition of non-controlling interest by the Company Ending Balance Descirption of management services agreement Ownership percentage Common stock shares issued in exchange Ownership retained percent Board of directors Consultant [Member] Orange County Research Center [Member] Pellecome [Member] Charles River Laboratories, Inc. [Member] Alpine Creek [Member] BICX Holding Company LLC [Member] January 5, 2024 [Member] Advisory services agreement description Renumeration amount Monthly retainer fee converted Payment of clinical services Total cost and attorney's fees payment Attorney's fees received or awarded Attorney's fees awarded Settelment amount Accrued interest Interest rate Annual compensation Cash received Stock equivalent amount Compensation for services, description Remaining commitment Royalty amount due Total consideration amount Accounts receivables Payment received for services Payable commitment description Payable per treatment sold Profit holding percentage Common stock issued upon convertible debt Convertible Promissory Note Total Interest Payment Issuance price per share Conversion agreement description Selling, general and administrative Research and development Fair value on the acquisition date Upfront Purchase price Payments upfront purchase price Change in fair value upfront purchase price Fair value upfront purchase price Fair value on the acquisition date Royalty Payment Payments of royalty payment Change in fair value Royalty Payment Fair value royalty payment Net sales and profit sharing Upfront purchase price [Upfront purchase price 1] Seller for purchase of assets description Royalty payments period Revision of Prior Period [Axis] Series A Convertible Preferred Stock [Member] As Revised [Member] Revision [Member] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] As Reported [Member] Convertible Series A Preferred Stock [Member] Current assets: Cash Accounts receivable, net Grant receivable Inventory Prepaid expenses Total current assets Property and equipment, net Right to use assets Other assets: Intangible assets, net Goodwill Deposits, long term Total other assets Total assets LIABILITIES AND DEFICIT Current liabilities: Accounts payable and accrued expenses Lease liability, short term Notes payable, related parties, net of debt discount Total current liabilities Long term liabilities: Economic Injury Disaster loan, long term [Other Long-Term Debt, Noncurrent] Royalty liability Royalty obligation, net of discount Lease liability, long term Total liabilities Commitments and contingencies Deficit: Common stock, $0.001 par value; 750,000,000 shares authorized, 28,906,559 shares issued and outstanding as of March 31, 2026 Common stock subscribed Additional paid in capital Accumulated deficit Total deficit attributable to BioCorRx, Inc. Non-controlling interest Total deficit Total liabilities and deficit Total liabilities and deficit Preferred Stock Value ASSETS As Revised [Member] Revision [Member] As Reported [Member] Revenues, net Cost of goods sold [Cost of goods sold] Selling, general and administrative Impairment of intellectual property [Impairment of intellectual property] Depreciation and amortization [Depreciation, Amortization and Accretion, Net] Total operating expenses Loss from operations Loss on settlement of debt Grant income Total other income Loss before provision for income taxes Income taxes Net loss attributable to BioCorRx Inc. Net loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted Interest expense - related party Reported [Member] Common Stock Series B Convertible Preferred Stock Common Stock Subscribed Additional Paid-In Capital Accumulated Deficit Noncontrolling Interest Common stock issued for services rendered, amount Common stock issued in connection with subscription agreement, shares Common stock issued in connection with subscription agreement, amount Common stock issued in connection with conversion of promissory notes, shares [Common stock issued in connection with conversion of promissory notes, shares] Common stock issued in connection with conversion of promissory notes, amount [Common stock issued in connection with conversion of promissory notes, amount] Common stock issued in connection with acquisition of non-controlling interest, shares Common stock issued in connection with acquisition of non-controlling interest, amount Common stock issued in connection with issuance of promissory notes, shares [Common stock issued in connection with issuance of promissory notes, shares] Common stock issued in connection with issuance of promissory notes, amount [Common stock issued in connection with issuance of promissory notes, amount] Imputed interest for related party advances Depreciation and amortization [Other Depreciation and Amortization] Amortization of discount on royalty obligation Impairment of intellectual property Amortization of right-of-use asset Loss on settlement of debt [Loss on settlement of debt] Stock based compensation Accounts receivable Grant receivable [Grant receivable] Prepaid expenses Accounts payable and accrued expenses Royalty liability [Royalty liability] Upfront purchase price liability Lease liability Net cash used in operating activities Proceeds from common stock subscription and royalty agreement Payment to Economic Injury Disaster loan Payment of notes payable - related party Payment of notes payable Proceeds from notes payable - related party Net cash provided by financing activities Net increase in cash Interest paid Taxes paid Common stock issued in connection with conversion of related party promissory note [Common stock issued in connection with conversion of related party promissory note] Common stock issued in connection with issuance of promissory notes [Common stock issued in connection with issuance of promissory notes] Subsequent Event Type [Axis] Board of Directors [Member] Subsequent Event [Member] The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.